Cisplatin-Induced Acute Kidney Injury in Mice

Seven-week-old male C57BL/6 mice were purchased from HyoSung Science (Daegu, Republic of Korea). Before starting experiments, the mice were acclimated for 1 week under 20–24 °C on a 12/12 h light/dark cycle. Animal experiments were approved by the Institutional Animal Care and Use Committee of the Daegu Catholic University Medical Center (DCIAFCR-180312-20-Y). The mice were randomly grouped into four groups (n = 8 in each group): (1) control (Con) group; (2) OXA group; (3) cisplatin (CP) group; (4) cisplatin plus OXA (CP + OXA) group. The CP group and the CP + OXA group were injected intraperitoneally with cisplatin [15 mg/kg in 0.9% saline; Cayman Chemical, Ann Arbor, MI, USA]. The OXA group and the CP + OXA group were given an intraperitoneal injection of OXA (1 μmol/kg in phosphate-buffered saline (PBS); Tocris Bioscience, Bristol, UK) daily for 4 consecutive days, starting from 1 day prior to 0.9% saline or cisplatin injection. An equal volume of PBS was injected intraperitoneally into the CP group. The doses of cisplatin and OXA were chosen based on previous studies [16 (link),17 (link),18 (link),19 (link)]. At 72 h after cisplatin injection, the mice were sacrificed.